ESPR Esperion Therapeutics Inc.

RFK Announces Team-Wide Partnership with Esperion Therapeutics; Includes Primary Partnership for Brad Keselowski at the ’23 Daytona 500

RFK Announces Team-Wide Partnership with Esperion Therapeutics; Includes Primary Partnership for Brad Keselowski at the ’23 Daytona 500

NASCAR Champion Brad Keselowski to Run No. 6 NEXLIZET (bempedoic acid and ezetimibe) Ford in Famed Daytona 500

CONCORD, N.C., Jan. 11, 2023 (GLOBE NEWSWIRE) --  RFK Racing has announced that Esperion Therapeutics, a Michigan-based pharmaceutical company, has partnered with the team for a multi-year agreement pursuant to which Esperion will promote two cholesterol lowering treatments – NEXLIZET (bempedoic acid and ezetimibe) and NEXLETOL (bempedoic acid). NEXLIZET will be featured on Keselowski’s No. 6 Ford at this year’s Daytona Speedweeks, including the famed Daytona 500 on February 19. NEXLETOL will be featured throughout the season on Chris Buescher’s No. 17 Ford.

Headquartered in Ann Arbor, Michigan, Esperion discovers, develops, and commercializes innovative medicines and combinations to lower cholesterol, especially for patients whose needs aren’t being met by current treatment options.

“We’re thrilled to have Esperion, a company that is making waves in the pharmaceutical industry, on board with us,” said Steve Newmark, President of RFK Racing. “We look forward to working with Esperion to create engaging content around their two products in NEXLIZET and NEXLETOL and showcasing their debut on the No. 6 for the famed Daytona 500. We’re thankful to the team at Esperion and can’t wait to introduce them to the sport in a big way in 2023.”

In addition to the Daytona 500 (Feb. 19, 2:30 p.m. ET, FOX), Esperion will serve as a primary on the No. 6 Ford at the All-Star Race at North Wilkesboro Speedway (May 21, 8 p.m. ET, FS1) and RFK’s home track at Michigan (Aug. 6, 2:30 p.m. ET, USA).

The brand will serve as a primary on the No. 17 at Las Vegas (March 5, 3:30 p.m. ET, FOX), Martinsville Spring (April 16, 3 p.m. ET, FS1), and Martinsville Fall (Oct. 29, 2 p.m. ET, NBC).

“We’re excited to partner with RFK Racing to increase brand awareness, and this sponsorship provides ample opportunities for community engagement and education to their large and diverse consumer base to advance awareness about the benefits of lowering LDL cholesterol and improving cardiovascular health,” said Sheldon Koenig, Esperion’s President and CEO.

Keselowski enters his second season at RFK and 14th full season in the NASCAR Cup Series (NCS). With 35 Cup wins to his credit, he is set to make his 500th Cup start in 2023. Buescher, now in his fourth season back with RFK, embarks on his eighth full-time season of Cup competition.

At Daytona and Michigan combined, Keselowski has 19 combined top-10 efforts, including a win in the 2022 Duels where RFK swept the season-opening exhibition qualifying races. At the two-mile Michigan facility, he has top-10s in half of his all-time starts in his home state.

Coming off a victory in the historic Bristol Night Race, Buescher will carry the NEXLETOL banner at another short track in Martinsville, in addition to the race at Las Vegas.

The 2023 NASCAR season unofficially kicks off with the Clash at the Coliseum (8 p.m. ET, FOX) on Sunday, Feb. 5, in Los Angeles. Coverage of Daytona 500 week begins on Wednesday, Feb. 15, with full-field qualifying, followed by the Duels on Thursday, and a pair of practice sessions set to take place Friday and Saturday.

About Esperion

Esperion works hard to make our medicines easy to get, easy to take, and easy to have. We discover, develop, and commercialize innovative medicines and combinations to lower cholesterol, especially for patients whose needs aren’t being met by the status quo. Our entrepreneurial team of industry leaders is inclusive, passionate and resourceful. We are singularly focused on managing cholesterol so you can improve your health easily. For more information, please visit esperion.com and follow us on Twitter at /EsperionInc. 

About RFK Racing

RFK Racing, in its 36th season in 2023, features an ownership lineup pairing one of the sport’s most iconic names, Jack Roush, along with NASCAR Champion, Brad Keselowski, and Fenway Sports Group owner John Henry. Roush initially founded the team in 1988 and it has since become one of the most successful racing operations in the world, propelling him to be the first NASCAR owner to amass three hundred wins and capturing eight championships, including back-to-back NASCAR Cup titles in 2003 and 2004. Keselowski, a former owner in the NASCAR Truck Series, brings to the team a championship mindset himself having won the 2012 NASCAR Cup Series Championship. In 2007, Roush partnered with Henry, who also owns Major League Baseball’s Boston Red Sox, English Premier League’s Liverpool F.C., and the NHL’s Pittsburgh Penguins, to form Roush Fenway Racing. Off the track, RFK is a leader and proven winner in NASCAR marketing solutions, having produced multiple award-winning social media, digital content and experiential marketing campaigns. Visit , and follow the team on all social platforms @rfkracing.

Contact:

Esperion Corporate Communications





EN
11/01/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Esperion Therapeutics Inc.

 PRESS RELEASE

Esperion Announces Pricing of Public Offering of Common Stock

Esperion Announces Pricing of Public Offering of Common Stock ANN ARBOR, Mich., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (“Esperion”) (Nasdaq: ESPR), a commercial stage biopharmaceutical company that focuses on developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C), today announced the pricing of an underwritten public offering of 30,000,000 shares of its common stock at a public offering price of $2.50 per share. In addition, Esperion has granted the underwrit...

 PRESS RELEASE

Esperion Announces Proposed Public Offering of Common Stock

Esperion Announces Proposed Public Offering of Common Stock ANN ARBOR, Mich., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (“Esperion”) (Nasdaq: ESPR), a commercial stage biopharmaceutical company that focuses on developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C), today announced that it has commenced an underwritten public offering of shares of its common stock. Esperion also intends to grant the underwriters a 30-day option to purchase up to an additional fif...

 PRESS RELEASE

Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy’s Lab...

Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy’s Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Prior to April 19, 2040 ANN ARBOR, Mich., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Dr. Reddy’s Laboratories, Inc. and its affiliate Dr. Reddy’s Laboratories Ltd. (together, Dr. Reddy’s Laboratories). This agreement resolves the patent litigation brought by Esperion against Dr. Reddy’s Laboratories in response to Dr. Redd...

 PRESS RELEASE

Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETO...

Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL® in Japan for the Treatment of Hypercholesterolemia Third Largest Global Market for Cardiovascular Prevention Represents Significant Global Growth Opportunity for NEXLETOL ANN ARBOR, Mich., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that Otsuka Pharmaceutical Co., Ltd. (Otsuka), the Company’s partner for the development and commercialization of NEXLETOL® (bempedoic acid) tablets in Japan, has received approval from the Japanese Ministry of Health, Labour and Welfare to market NEXLETOL...

 PRESS RELEASE

Esperion’s Bempedoic Acid Receives Level 1a Recommendation in Updated ...

Esperion’s Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias – Bempedoic Acid Receives Strongest Endorsement from ESC/EAS Guidelines Based on Compelling and Practice-Changing Evidence – – Guideline Recognition of ‘Strike Early and Strike Strong’ Approach with Early Combination Lipid-Lowering Therapy Affirms Continued Development of Company’s Oral Triple Combination Therapies in U.S. – ANN ARBOR, Mich., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today welcomed the inclusion of bempedoic acid as the only n...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch